🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Pancreatic Cancer Screening Using the Enzeavour Assay in Japan

RecruitingNAAges 20 Years - anyAllCosomil, Inc.
NCT07605819 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score above 0.369 will undergo diagnostic work-up as clinically indicated. The primary outcome is pancreatic cancer detection rate within 12 months after the index blood draw, and the secondary outcome is positive predictive value.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Asymptomatic adults attending participating facilities for routine health checkups, organized cancer screening, or both * Able to understand the study procedures and provide written informed consent before enrollment Exclusion Criteria: * Documented clinical history of pancreatic cancer * Considered unable or unwilling to undergo any required diagnostic imaging modality (MRCP, EUS, or contrast-enhanced CT) after a positive index test result * Any medical, psychological, or social condition that, in the opinion of the principal investigator at each participating site, makes participation inappropriate or compromises study integrity
💊

What it tests

  • Enzeavour Pancreatic Cancer Assay
📍

Where

48 sites
Aichi Medical University Hospital
Nagakute, Japan
Nagoya University Hospital
Nagoya, Japan
Hiroshima University Hospital
Hiroshima, Japan
JA Onomichi General Hospital
Onomichi, Japan
Obihiro Kosei Hospital
Obihiro, Japan
Keijinkai Maruyama Clinic
Sapporo, Japan
Teine Keijinkai Hospital
Sapporo, Japan
Hotel Okura Kobe Clinic
Kobe, Japan

…and 40 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy